Latest DNAtrix Inc. Stories
SAN DIEGO, June 17, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status for its lead product, DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma. The FDA gives Fast Track status to facilitate the development of new products for serious or life-threatening conditions which demonstrate the potential to address unmet medical needs,...
- The offense of persistently instigating lawsuits, typically groundless ones.
- An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
- Sale or purchase of positions in church or state.